UroGen Pharma (NASDAQ:URGN) Announces Earnings Results, Misses Estimates By $0.11 EPS

UroGen Pharma (NASDAQ:URGN) announced its earnings results on Monday. The company reported ($0.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11), Zacks reports. The company had revenue of $24.57 million for the quarter, compared to analysts’ expectations of $25.25 million.

UroGen Pharma Price Performance

NASDAQ URGN opened at $10.82 on Wednesday. The company has a 50 day simple moving average of $10.45 and a 200-day simple moving average of $11.70. The company has a debt-to-equity ratio of 4.77, a current ratio of 9.00 and a quick ratio of 8.77. The firm has a market capitalization of $253.77 million, a price-to-earnings ratio of -3.43 and a beta of 1.12. UroGen Pharma has a 52-week low of $9.03 and a 52-week high of $20.70.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. HC Wainwright decreased their target price on shares of UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday. LADENBURG THALM/SH SH began coverage on shares of UroGen Pharma in a research report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price objective for the company. Finally, D. Boral Capital restated a “buy” rating and set a $25.00 price objective on shares of UroGen Pharma in a research report on Monday. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $38.20.

Insider Transactions at UroGen Pharma

In related news, General Counsel Jason Drew Smith sold 7,379 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $82,202.06. Following the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at approximately $294,853.52. This trade represents a 21.80 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the transaction, the insider now directly owns 145,666 shares in the company, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their position. The disclosure for this sale can be found here. 5.10% of the stock is owned by insiders.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.